Genus PLC
LSE:GNS
Genus PLC
Net Income (Common)
Genus PLC
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Net Income (Common)
-£4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Net Income (Common)
-$235.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-116%
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Net Income (Common)
-£146m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Net Income (Common)
-$169m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Income (Common)
-£51.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Niox Group PLC
LSE:NIOX
|
Net Income (Common)
£3.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genus PLC
Glance View
Amidst the rolling countryside of Britain, Genus PLC has quietly but profoundly reshaped the agricultural landscape since its formation. With roots tracing back to the British government's Milk Marketing Board, Genus blossomed into an influential player at the intersection of biotechnology and farming. This was not by chance, but through a strategic evolution into a global pioneer in animal genetics. At the heart of their operations, Genus enhances animal breeding by leveraging cutting-edge science, particularly the technology of selective breeding and genetics. They focus primarily on two types of livestock: bovine (cattle) and porcine (pigs), catering to agricultural sectors worldwide. Essentially, through their subsidiaries—ABS Global, focusing on cattle, and PIC, specializing in pigs—the company maximizes genetic improvements, aiding farmers in producing leaner, more disease-resistant, and ultimately more productive livestock. The business model of Genus PLC revolves around the intricate science of animal genetics and the commercial viability it crafts from this foundation. By developing genetically superior livestock, they provide a distinct competitive advantage to farmers who seek more yield with less resource input. The company harnesses sophisticated techniques like genomics and advanced biotechnologies, including gene editing, to achieve these outcomes. With each genetic line licensed, Genus receives a license fee, ensuring a steady stream of revenue. Additionally, sales channels are bolstered by continuous consultative partnerships with farmers to enhance productivity, cementing a cycle of value that perpetuates mutual growth. By marrying science with agricultural prosperity, Genus PLC remains a vanguard in a field where innovation is as essential as the soil itself.
See Also
What is Genus PLC's Net Income (Common)?
Net Income (Common)
-4m
GBP
Based on the financial report for Dec 31, 2024, Genus PLC's Net Income (Common) amounts to -4m GBP.
You don't have any saved screeners yet